Diligence memo · auto-generated · as of July 2, 2026
Inozyme Pharma, Inc.
Inozyme Pharma, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Inozyme Pharma, Inc. operates in Pharmaceuticals, based in BOSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Inozyme Pharma, Inc. has raised $116M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $67M on 2018-11-09.
Most recent recorded round closed around 2018-11-09.
Valuation (modeled)modeled
Provath models Inozyme Pharma, Inc. at approximately $2.4B (range $219M–$6.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.02× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era. Within the normal band (102% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 7.6 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 92% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Amplyx Pharmaceuticals, Inc., Ligand Pharmaceuticals Inc, Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.